StreetInsider.com News Articles

Form 8-K NovoCure Ltd For: Oct 01

Thu, 01 Oct 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20261001/27132665.html

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

Thu, 01 Oct 2026 09:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

“The approval of Optune Pax provides a promising new treatment option for locally advanced pancreatic cancer, a disease with an urgent need for effective therapies,” said Makoto Ueno, MD, PhD, Director, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama. “In the Phase 3 PANOVA-3 trial for Optune Pax, there was a statistically significant improvement in overall survival and pain progression was

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

Thu, 01 Oct 2026 09:00:00 -0400

Novocure to Report Third Quarter 2026 Financial Results

Thu, 01 Oct 2026 07:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.

Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 29, to discuss the company’s financial results for the three-month period that ended September 30, 2026.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and

Novocure to Report Third Quarter 2026 Financial Results

Thu, 01 Oct 2026 07:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.

Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 29, to discuss the company’s financial results for the three-month period that ended September 30, 2026.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and

NovoCure reports data breach affecting over 1,400 patient records

Tue, 01 Sep 2026 07:03:43 -0400

NovoCure Limited (NASDAQ: NVCR) disclosed that an unauthorized party gained access to some of its information systems in mid-August 2026, exposing data from more than 1,400 U.S. patient records and a smaller set of additional patient files.

According to the company's filing, the exposed data included internal patient ID numbers for over 1,400 U.S. patients, though no patient names or other identifying information were included for that group. Fewer than 50 patients in the western United States had additional identifying information exposed. The breach also included general contact information for healthcare providers and NovoCure employees, such as job titles and phone

NovoCure Ltd. (NVCR) PT Lowered to $32 at H.C. Wainwright

Fri, 24 Jul 2026 07:47:38 -0400

(Updated - July 24, 2026 7:47 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $32.00 (from $46.00) while maintaining a Buy rating.

The analyst commented: "Record revenue quarter driven by growth across geographies and all marketed therapies; guidance revised upward. The company reported 2Q26 revenue of $183.6M, consisting of $177M for GBM, $5.4M for NSCLC, and $1.6M for LA-PAC, representing 5.5% QoQ growth, compared to FactSet consensus of -0.8%, and our estimate of -0.2%. Revenue growth was observed in all markets, with a record number of active GBM patients in the US, though

NovoCure Ltd. (NVCR) PT Lowered to $32 at H.C. Wainwright

Fri, 24 Jul 2026 07:47:38 -0400

(Updated - July 24, 2026 7:47 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $32.00 (from $46.00) while maintaining a Buy rating.

NovoCure Ltd. (NVCR) PT Raised to $20 at Wedbush

Fri, 24 Jul 2026 07:47:32 -0400

Wedbush analyst David Nierengarten raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $20.00 (from $18.00) while maintaining a Neutral rating.

NovoCure Ltd. (NVCR) PT Raised to $20 at Wells Fargo

Fri, 24 Jul 2026 06:29:38 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $20.00 (from $17.00) while maintaining a Equal Weight rating.

Form 144 NovoCure Ltd Filed by: Leupin Nicolas

Thu, 23 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260723/26808402.html

Form 144 NovoCure Ltd Filed by: Leupin Nicolas

Thu, 23 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260723/26808402.html

Novocure (NVCR) Tops Q2 EPS by 20c; offers guidance

Thu, 23 Jul 2026 07:02:35 -0400

Novocure (NASDAQ: NVCR) reported Q2 EPS of ($0.13), $0.20 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $183.6 million versus the consensus estimate of $172.72 million.

GUIDANCE:

Novocure sees FY2026 revenue of $710-725 million, versus the consensus of $708.7 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.

Novocure (NVCR) Tops Q2 EPS by 20c; offers guidance

Thu, 23 Jul 2026 07:02:35 -0400

GUIDANCE:

Novocure sees FY2026 revenue of $710-725 million, versus the consensus of $708.7 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.

Form 8-K NovoCure Ltd For: Jul 23